Skocz do zawartości


Kwas rumenowy (CLA)

- - - - -

  • Proszę się zalogować aby odpowiedzieć



    Na KFD prawie jak w domu ;)

  • Użytkownicy
  • PipPipPipPipPip
  • 1368 postów
  • Wiek: 25
    • Płeć:Mężczyzna
    • Miasto:Poznań
    • Staż [mies.]: 0

    to juz wiem czemu dostalam rozpiske z CLA do kazdego posilku codziennie :) dzieki za arta.

    Warto wspomnieć, że suplementy a CLA z pożywienia to różna sprawa :)

    The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain.

    OBJECTIVE: The incidence of obesity and overweight in the US has increased considerably during the past two decades and currently affects 65% of the adult population. Research has indicated that small, yet irreversible, gains during the holiday season contribute to increases in weight during adulthood. Conjugated linoleic acid (CLA), a naturally occurring dietary fatty acid, has been found to reduce weight gain and dramatically decrease fat mass in animals. Although research in humans has shown inconsistent results, most studies have been of insufficient duration or have utilized body composition methods that are less accurate than the currently accepted criterion.

    DESIGN: Randomized, double-blind, placebo-controlled study of 3.2 g/day CLA for 6 months.

    SUBJECTS: Forty healthy, overweight subjects (age: 18-44 years; body mass index: 25-30 kg/m(2)).

    MEASUREMENTS: Body composition by the four-compartment model, resting metabolic rate (RMR) by indirect calorimetry, self-reported physical activity and dietary intake, and blood chemistries were determined at baseline and after 6 months. Body weight was measured monthly during the pre-holiday season (August-October), holiday season (November-December) and post-holiday season (January-March). Adverse events were assessed monthly.

    RESULTS: Compared to CLA, the placebo group showed a greater rate of weight gain during the holiday season (P=0.01). Within the placebo group, holiday weight change was significantly greater compared to the pre-holiday period (August-October) (P=0.03). Six-month change in body composition was improved with CLA compared to placebo (P=0.02), and body fat was significantly reduced within the CLA group (-1.0+/-2.2 kg, P=0.05). CLA had no effect on RMR, physical activity or dietary intake. The rate of reported negative emotions decreased significantly with CLA, although there was no difference in any other category of adverse event. In comparison to the placebo, CLA did not affect insulin resistance, blood lipids and markers of liver function or markers of inflammation, with the exception of a significant decrease in a biomarker of endothelial dysfunction.

    CONCLUSION: CLA supplementation among overweight adults significantly reduced body fat over 6 months and prevented weight gain during the holiday season. Although no adverse effects were seen, additional studies should evaluate the effect of prolonged use of CLA.


    dwie grupy:
    -przyjmujaca CLA w ilosci 3,2g/dzien przez okres 6-ciu miesiecy

    po 6-ciu miesiacach grupa przyjmująca CLA w porownaniu do grupy placebo utracila 1,0kg ! tkanki tluszczowej!

    1 kilogram!!

    teraz sobie policzcie - 3,2grama CLA x ~180dni - aby spalic 1,0kg tluszczu wiecej

    Effect of conjugated linoleic acid on body fat accretion in overweight or obese children.

    BACKGROUND: Conjugated linoleic acid (CLA) is a supplemental dietary fatty acid that decreases fat mass accretion in young animals.

    OBJECTIVE: The aim of this study was to determine CLA's efficacy with regard to change in fat and body mass index (BMI; in kg/m(2)) in children.

    DESIGN: We conducted a 7 +/- 0.5-mo randomized, double-blind, placebo-controlled trial of CLA in 62 prepubertal children aged 6-10 y who were overweight or obese but otherwise healthy. The subjects were randomly assigned to receive 3 g/d of 80% CLA (50:50 cis-9,trans-11 and trans-10,cis-12 isomers) or placebo in chocolate milk.

    RESULTS: Fifty-three subjects completed the trial (n = 28 in the CLA group, n = 25 in the placebo group). CLA attenuated the increase in BMI (0.5 +/- 0.8) compared with placebo (1.1 +/- 1.1) (P = 0.05). The percentage change in body fat measured by dual-energy X-ray absorptiometry was smaller (P = 0.001) in the CLA group (-0.5 +/- 2.1%) than in the placebo group (1.3 +/- 1.8%). The change in abdominal body fat as a percentage of total body weight was smaller (P = 0.02) in the CLA group (-0.09 +/- 0.9%) than in the placebo group (0.43 +/- 0.6%). There were no significant changes in plasma glucose, insulin, or LDL cholesterol between groups. Plasma HDL cholesterol decreased significantly more (P = 0.05) in the CLA group (-5.1 +/- 7.3 mg/dL) than in the placebo group (-0.7 +/- 8 mg/dL). Bone mineral accretion was lower (P = 0.04) in the CLA group (0.05 +/- 0.03 kg) than in the placebo group (0.07 +/- 0.03 kg). Reported gastrointestinal symptoms did not differ significantly between groups.

    CONCLUSIONS: CLA supplementation for 7 +/- 0.5 mo decreased body fatness in 6-10-y-old children who were overweight or obese but did not improve plasma lipids or glucose and decreased HDL more than in the placebo group. Long-term investigation of the safety and efficacy of CLA supplementation in children is recommended.


    badano wplyw CLA na otyle dzieci

    dwie grupy:
    -grupa przyjmujaca CLA 80% w ilosci 3g/dzien przez okres 7miu miesiecy

    -grupa przyjmujaca CLA stracila 0,5% taknki tluszcowej
    gdy grupa placebo dodala kolejny 1,1%
    -w obrebie pasa poziom tkanki tluszczowej wynosil odpowiednio -0,09% (+/- 1% ) i +0,43%
    -nie bylo istatnych zmian w surowicy krwi jesli chodzi o poziom glukozy,insuliny i LDL

    -zanotowano u grupy CLA spadek HDL o -5.1mg/dL,kiedy u grupy placebo -0.7!
    -zawartosc mineralów kosciach tez mniejsza 0.05 vs 0.07kg

    Conjugated linoleic acid supplementation in humans: effects on body composition and energy expenditure.

    Recent animal studies have demonstrated that dietary conjugated linoleic acid (CLA) reduces body fat and that this decrease may be due to a change in energy expenditure. The present study examined the effect of CLA supplementation on body composition and energy expenditure in healthy, adult women. Seventeen women were fed either a CLA capsule (3 g/d) or a sunflower oil placebo for 64 d following a baseline period of 30 d. The subjects were confined to a metabolic suite for the entire 94 d study where diet and activity were controlled and held constant. Change in fat-free mass, fat mass, and percentage body fat were unaffected by CLA supplementation (0.18+/-0.43 vs. 0.09+/-0.35 kg; 0.01+/-0.64 vs. -0.19+/-0.53 kg; 0.05+/-0.62 vs. -0.67+/-0.51%, placebo vs. CLA, respectively). Likewise, body weight was not significantly different in the placebo vs. the CLA group (0.48+/-0.55 vs. -0.24+/-0.46 kg change). Energy expenditure (kcal/min), fat oxidation, and respiratory exchange ratio were measured once during the baseline period and during weeks 4 and 8 of the intervention period. At all three times, measurements were taken while resting and walking. CLA had no significant effect on energy expenditure, fat oxidation, or respiratory exchange ratio at rest or during exercise. When dietary intake was controlled, 64 d of CLA supplementation at 3 g/d had no significant effect on body composition or energy expenditure in adult women, which contrasts with previous findings in animals.


    dwie grupy spozywajace przez 64 dni
    -placebo (olej ze slonecznika)
    -CLA w ilosci 3g/dzien

    wnioski po 64 dniach (placebo vs. CLA):
    LBM: 0.18kg vs. 0.09
    takanka tluszczowa: 0.01kg vs. -0.19
    BF: 0.05% vs. -0.67
    wga coiala: 0.48kg vs. -0.24

    zmiany minimalne!

    Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain.

    BACKGROUND: Conjugated linoleic acid (CLA) is marketed as a safe, simple, and effective dietary supplement to promote the loss of body fat and weight. However, most previous studies have been of short duration and inconclusive, and some recent studies have questioned the safety of long-term supplementation with CLA.

    OBJECTIVE: Our aim was to assess the effect of 1-y supplementation with CLA (3.4 g/d) on body weight and body fat regain in moderately obese people.

    DESIGN: One hundred twenty-two obese healthy subjects with a body mass index (in kg/m2) > 28 underwent an 8-wk dietary run-in with energy restriction (3300-4200 kJ/d). One hundred one subjects who lost >8% of their initial body weight were subsequently randomly assigned to a 1-y double-blind CLA (3.4 g/d; n = 51) or placebo (olive oil; n = 50) supplementation regime in combination with a modest hypocaloric diet of -1250 kJ/d. The effects of treatment on body composition and safety were assessed with the use of dual-energy X-ray absorptiometry and with blood samples and the incidence of adverse events, respectively.

    RESULTS: After 1 y, no significant difference in body weight or body fat regain was observed between the treatments. The CLA group (n = 40) regained a mean (+/-SD) 4.0 +/- 5.6 kg body weight and 2.1 +/- 5.0 kg fat mass compared with a regain of 4.0 +/- 5.0 kg body weight and 2.7 +/- 4.9 kg fat mass in the placebo group (n = 43). No significant differences in reported adverse effects or indexes of insulin resistance were observed, but a significant increase in the number of leukocytes was observed with CLA supplementation.

    CONCLUSION: A 3.4-g daily CLA supplementation for 1 y does not prevent weight or fat mass regain in a healthy obese population.

    badano wplyw CLA w zapobieganiu powstawaniu tłuszczu, powstawaniu efektu jo jo
    122 osoby zostaly podzielone na dwie grupy:
    -grupe przyjmujaca CLA w ilosci 3,4g/dzien

    po roku(!) nie zauwazono zadnych zmian u tych grup
    ponadto grupa CLA prztyla 4,0kg gdzie 2,1kg to tluszcz
    a grupa placebo prztyla tez 4,0kg gdzie 2,7kg to tluszcz

    CLA nie zapobiega powstawaniu tluszczu!

    Conjugated linoleic acid intake in humans: a systematic review focusing on its effect on body composition, glucose, and lipid metabolism

    Studies performed on different species show that the consumption of conjugated linoleic acid (CLA) leads to a loss of fat and total body weight, reduces the plasma concentrations of total and LDL cholesterol, and has an antiinflammatory effect. This article reviews the clinical trials on human beings that evaluate how mixtures of CLA isomers administered as supplements or CLA-enriched products can affect total body weight, body composition, plasma lipid profile, glycemia, insulinemia, insulin sensitivity, lipid oxidation, and inflammation. After analyzing the few studies published to date in reduced samples of healthy humans or patients with overweight, obesity, metabolic syndrome, or diabetes, we deduce that there is not enough evidence to show that conjugated linoleic acid has an effect on weight and body composition in humans. However, some of these studies have observed that the administration of various CLA isomers has adverse effects on lipid profile (it decreases HDL cholesterol concentration and increases Lp(a) circulating levels), glucose metabolism (glycemia, insulinemia or insulin sensitivity), lipid oxidation, inflammation, or endothelial function. Therefore, long-term randomized clinical trials, controlled with placebo, need to be made in large samples of patients to evaluate the efficacy and safety of CLA isomers before its indiscriminate use in human beings can be recommended.


    po analizie kilku badan - wyciagnieto wniosek ze nie ma jednoznaczych przeslanek aby stwiredzic ze CLA pomaga w walce z nadwaga,otyloscia,cukrzyca,zespolem metabolicznym
    Zespół metaboliczny to grupa czynników ryzyka, do których zalicza się otyłość brzuszną, zmniejszoną zdolność do metabolizowania glukozy (insulinooporność), dyslipidemię (zaburzenie gospodarki lipidowej) i nadciśnienie tętnicze. Pacjenci z zespołem metabolicznym znajdują się w grupie podwyższonego ryzyka rozwoju choroby sercowo-naczyniowej i/lub cukrzycy typu 2.

    Jednak zauwazona ze podajac rozne izomry CLA rozny moga wywierac wplyw - rozwniez negatywny!
    -wzrost LDL
    -spadek HDL
    -hiperisnulinizm (wieksze wydzielanie insuliny)

    Styknie chyba tyle, więcej znajdziecie jak dobrze poszukacie u konkurencji.
    • 0



    • Użytkownicy
    • PipPipPipPip
    • 801 postów
  • Wiek: 32
    • Płeć:Kobieta
    • Miasto:Zabrze
    dobry artykuł!
    • 0

    0 użytkowników czyta ten temat

    0 użytkowników, 0 gości, 0 anonimowych użytkowników

     Zamknij okienko